Trupanion NASDAQ: TRUP spent years telling investors the compelling story about pet insurance. Yet despite rising revenue over the years, Trupanion has struggled to translate that growth into profits.
Now, with the company’s first quarter building on positive results from 2025, Trupanion is delivering record margins, a profitable beat, and strong subscriber retention.
But investors seem cautious. Growth may not be the problem facing the company. Compared to other countries, the United States lags far behind in pet insurance enrollment. Instead, animal inflation and industry competition could be the reason for investors to lose momentum and may need more patience.
Trupanion Delivers Strong Financial Results
Trupanion is rarely cited when it comes to insurance agents. It doesn’t pay a dividend, and cat and dog subscription insurance is a niche that rarely attracts the attention of investors. This company is also unusual in the insurance world because its policies are made monthly, rather than annual contracts that customers renegotiate every year.
The company’s first quarter results showed however that its model is working. In the first three months of the year, Trupanion reported that revenue rose 12% to $384 million compared to a year ago and exceeded expectations.
The company’s net income swung from a loss of $1.5 million a year earlier to a profit of $4.9 million, or 11 cents per share, more than 50% above analysts’ expectations. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 42% to $17.4 million,
While the earnings beat is noteworthy, operating margins tell a more important story. Trupanion’s subscription adjusted operating margin increased to 14.2%, a first-quarter record, from 12.9%. And adjusted operating income increased 29% year over year to more than $40 million.
Subscriber Loyalty Remains Strong
Trupanion’s business extends beyond its direct cat and dog insurance operations in the United States. The company also operates affordable Furkin and PHI Direct brands in Canada, employer programs, and pet health products. Its VetDirect Pay allows the integration of its insurance into veterinary claims plans. In the past few years, the company has also expanded through acquisitions in several European countries, which remain a small part of its business with only about 64,000 pets covered.
For a company built on monthly subscriptions, that line item is important, and it usually tells a good story.
Overall, subscription revenue for the quarter increased 16% to $269.5 million on a 5% increase in registered pets to 1.1 million. Across all lines of business, total registered pets were down 2% year-on-year. However, monthly income per animal increased to $85.79 compared to $77.53 last year.
This growth has been largely fueled by the apparent loyalty among subscribers. As of March 31, Trupanion reported a monthly retention rate of 98.35%, which means less than two out of every 100 subscribers have canceled.
In total, the company announced in May that it had reached more than $4 billion in animal invoices paid on behalf of policyholders.
Competition and Rising Costs Still Matter
However, given the nature of the business, investors cannot simply assume the smooth path achieved. With its monthly subscription model, the company can deal with potential volatility and price pressure.
Competition is increasing in the financial services sector. Insurers, direct-to-consumer startups, and employer-benefit pet insurance plans are all included or expanded into the category. Across the country, Lemonade NYSE: LMNDMetLife NYSE: METand Chubb’s Healthy Paws unit NYSE: CBare among others in the category.
On the other hand, Trupanion’s distribution model relies heavily on recommendations from veterinarians, and that provides some protection. However, maintaining that requires continued investment in animal welfare and product availability. Costs for new subscribers are also rising, rising to $315 per quarter from $267.
Meanwhile, veterinary costs have skyrocketed over the past decade, driven by advances in veterinary medicine that now include MRI imaging, cancer treatment, orthopedic surgery, and other procedures that can cost thousands of dollars.
Wall Street Remains Cautiously Optimistic
Trupanion Stock Forecast Today
$42.25
79.60% convertedHold on
Based on 6 Analyst Ratings
| Current Price | $23.53 |
|---|---|
| High Forecast | $59.00 |
| Average prediction | $42.25 |
| Low Prognosis | $31.00 |
Trupanion Stock Forecast Details
Analyst opinion, as well as the company’s stock price, reflects this tension.
Despite the improved results, the company’s shares are down more than 35% since the beginning of the year.
Last year, it was down more than 50%.
And while two analysts have given a buy rating to the stock, three analysts recommend a Hold, and one suggests a Sell, indicating how fragile the outlook remains.
Overall, the company holds a hold rating.
Even with a hold rating, the company’s lowest 12-month price target is $31, still above current trading levels. The target price is $42.25, more than 75% upside.
Potential Growth Can Reward Patience
For investors considering Trupanion, patience may be key. Pet insurance remains incredibly underfunded in North America, so there is room for growth. In the United Kingdom and Sweden, for example, pet insurance rates are well into the double digits. In the United States and Canada, the number is in the low single digits.
The first quarter results also deserve attention. Record operating margins and a strong earnings beat should not be overlooked, along with continued evidence that the subscription model is generating the kind of customer loyalty that sustains long-term economics.
For retail investors who are comfortable with a company that continues to prove its profit story, TRUP deserves a spot on the research list.
That said, this is not a stock for investors who need certainty or income. The company is still in the process of proving profitability. The next one or two quarterly reports will probably clarify. The first quarter of 2026 was quite encouraging. But in Trupanion’s case, the full story continues to be written.
Before you consider Trupanion, you’ll want to hear this.
MarketBeat tracks Wall Street’s top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Trupanion wasn’t on the list.
Although Trupanion currently has a hold rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
The space race is growing fast, and you don’t have to get in early on SpaceX to take advantage. This report shows seven space stocks you can buy today that are likely to grow as rockets, satellites, defense, space internet, and new space technologies become more important.
Get This Free Report
